https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-11-25 16:36:202016-11-25 16:38:002012 ASH: Results from Dose Escalation Phase of Randomized Phase 1-2 FIH Study of SGI-110
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-11-23 16:38:392016-11-25 16:38:582012 AACR: Chemosensitizing effects of DNA methylation inhibitor SGI-110 in Ovarian Cancer
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-11-20 16:39:062016-11-25 16:39:262012 AACR: SGI-110, a novel SQ second generation DNA hypomethylating agent
https://astx.com/wp-content/uploads/2019/11/logo_white.png00webadminhttps://astx.com/wp-content/uploads/2019/11/logo_white.pngwebadmin2012-11-15 16:39:312016-11-25 16:39:522012 AACR: Scale up & development of a process for a low volume subcutaneous formulation of SGI-110
